KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Change in Receivables (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Change in Receivables for 8 consecutive years, with $5.5 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 516.69% to $5.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.6 million through Dec 2025, up 130.93% year-over-year, with the annual reading at $8.6 million for FY2025, 130.93% up from the prior year.
  • Change in Receivables hit $5.5 million in Q4 2025 for Adaptive Biotechnologies, up from $536000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $13.5 million in Q4 2022 to a low of -$9.1 million in Q1 2023.
  • Historically, Change in Receivables has averaged $2.0 million across 5 years, with a median of $1.5 million in 2022.
  • Biggest five-year swings in Change in Receivables: soared 4606.97% in 2022 and later crashed 1132.37% in 2024.
  • Year by year, Change in Receivables stood at $287000.0 in 2021, then skyrocketed by 4606.97% to $13.5 million in 2022, then crashed by 49.91% to $6.8 million in 2023, then plummeted by 86.71% to $899000.0 in 2024, then soared by 516.69% to $5.5 million in 2025.
  • Business Quant data shows Change in Receivables for ADPT at $5.5 million in Q4 2025, $536000.0 in Q3 2025, and $702000.0 in Q2 2025.